A Multi-Center International Survey Related to the Nutritional Support after Hematopoietic Stem Cell Transplantation Endorsed by the ASIA Pacific Blood and Marrow Transplantation (APBMT)

Background: The nutritional support after hematopoietic stem cell transplantation (HSCT) has not been well established due to the scarcity of clinical trials. To conduct international clinical trials in Asia, we performed the questionnaire survey to investigate the current standard of nutritional support after HSCT. Method: We sent the questionnaire to the physicians nominated by the Asia Pacific Blood and Marrow Transplantation (APBMT) members of each country/ region. Result: We received 15 responses from 7 different countries/regions. The target calorie amount is 1.0 - 1.3 × basal energy expenditure (BEE) in 11 institutes when partial parenteral nutrition is used. When total parenteral nutrition (TPN) is used, the target calorie amount is 1.0 - 1.3 × BEE in 9 institutes and 1.3 - 1.5 × BEE in 4 institutes. Lipid emulsion is routinely used in 12 institutes. Multivitamins and trace elements are routinely added to TPN used in most institutes. It is still uncommon to use the immunonutrition. Blood glucose levels are routinely monitored in all institutes, but the target range varies (<110 in 2 institutes, <150 in 4 institutes, and <200 in 8 institutes). Conclusions: Basic nutritional support is similar in participating institutes. However, the target glucose level varies and the use of immunonutrition is rather rare. These points can be the theme of future clinical trials.

EFFECTS OF BLOOD TRANSFUSION ON BONE MARROW TRANSPLANTATION IN RATS WITH RADIATION-BURN COMBINED INJURY

The effects of pre-irradiation blood transfusion(BT)on survival rateof radiation-burn combinedly injured rats receiving bone marrow transplantation(BMT) were studied. It was found that after 9-11 Gy of radiation was given, the 90-daysurvival rate of the rats receiving BT(72%) and BMT was significantly higher than thatof those receiving BMT only(42%)(P<0.01).In those rats surviving over 100 days,cells of donor type could be found. In the first 30 days of surviving, the number of Tcells was significantly higher in the BMT alone group than in the group of BMT plusBT, but no difference In restoration of B cell was revealed. The findings suggest that BTcould promote the recipient's tolerance to BMT. The effects of BT on BMT are similarto those on skin grafting.

Effects of blood transfusion on bone marrow transplantation for the survival of rats after total lymphoid irradiation treated with cyclophosphamide

Rats,after inflicted with total lymphoid irradiation (TLI) of 10 Gy gamma rays (lethal dose) and treated with cyclophosphamide (CY),were further treated with bone marrow transplantation (BMT). Then the effects of blood transfusion (BT) on the therapeutic effects of BMT and the survival of the rats were observed. It was found that after TLI and CY treatment, the rats were further treated with BT and all the animals died in 4-12 d after TLI. The 60 day survival rate of the rats treated 1 d after BMT with BT from the same donor of bone marrow and that of those rats treated with BMT only was 10% and that of those rats treated 1 d before BMT with BT from the same donor of bone marrow or from another donor was 20% and 40% respectively (P<0. 05). And the rats treated 3 d before BMTwith BT from the same donor of bone marrow all died of allergic reaction in 4-10 d after TLI. When CY was administered in divided doses, the 60-day survival rate of the rats treated 1 d before BMT with BT from the same donor of bone marrow was increased to 80%(PM0. 01). These findings indicate that the effects of BT on the enhancement of the therapeutic effects of BMT on radiation injury is determined with the time of BT.

Hematopoietic stem cell transplantation for auto immune rheumatic diseases

Stem cells have their origins in the embryo and during the process of organogenesis, these differentiate into specialized cells which mature to form tissues. In addition, stem cell are characterized by an ability to indefinitely self renew. Stem cells are broadly classified into embryonic stem cells and adult stem cells. Adult stem cells can be genetically reprogrammed to form pluripotent stem cells and exist in an embroyonic like state. In the early phase of embryogenesis, human embryonic stem cells only exist transiently. Adult stem cells are omnipresent in the body and function to regenerate during the process of apoptosis or tissue repair. Hematopoietic stem cells(HSC) are adult stem cells that form blood and immune cells. Autoimmune responses are sustained due to the perennial persistence of tissue self autoantigens and/or auto reactive lymphocytes. Immune reset is a process leading to generation of fresh self-tolerant lymphocytes after chemotherapy induced elimination of self or autoreactive lymphocytes. This forms the basis for autologous HSC transplantation(HSCT). In the beginning HSCT had been limited to refractory autoimmune rheumatic diseases(AIRD) due to concern about transplant related mortality and morbidity. However HSCT for AIRD has come a long way with better understanding of patient selection, conditioning regime and supportive care. In this narrative review we have examined the available literature regarding the HSCT use in AIRD.

Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies

Hematopoietic stem cell transplant(HSCT) is a standard treatment for many hematological malignancies.Three different sources of stem cells, namely bone marrow(BM), peripheral blood stem cells(PBSC) and cord blood(CB) can be used for HSCT, and each has its own advantages and disadvantages. Randomized controlled trials(RCTs) suggest that there is no significant survival advantage of PBSC over BM in Human Leukocyte Antigen-matched sibling transplant for adult patients with hematological malignancies. PBSC transplant probably results in lower risk of relapse and hence better disease-free survival, especially in patients with high risk disease at the expense of higher risks of both severe acute and chronic graft-versus-host disease(GVHD).In the unrelated donor setting, the only RCT available suggests that PBSC and BM result in comparable overall and disease-free survivals in patients with hematological malignancies; and PBSC transplant results in lower risk of graft failure and higher risk of chronic GVHD.High level evidence is not available for CB in comparison to BM or PBSC. The risks and benefits of different sources of stem cells likely change with different conditioning regimen, strategies for prophylaxis and treatment of GVHD and manipulation of grafts. The recent success and rapid advance of double CB transplant and haploidentical BM and PBSC transplants further complicate the selection of stem cell source. Optimal selection requires careful weighing of the risks and benefits of different stem cell source for each individual recipient and donor. Detailed counseling of patient and donor regarding risks and benefits in the specific context of the patient and transplant method is essential for informed decision making.

Stem cell transplantation for spinal cord injury： a meta-analysis of treatment effectiveness and safety

OBJECTIVE： The aim of this study was to evaluate the effectiveness and safety of stem cell transplantation for spinal cord injury（SCI）.DATA SOURCES： PubM ed, EMBASE, Cochrane, China National Knowledge Infrastructure, China Science and Technology Journal, Wanfang, and Sino Med databases were systematically searched by computer to select clinical randomized controlled trials using stem cell transplantation to treat SCI, published between each database initiation and July 2016. DATA SELECTION： Randomized controlled trials comparing stem cell transplantation with rehabilitation treatment for patients with SCI. Inclusion criteria：（1） Patients with SCI diagnosed according to the American Spinal Injury Association（ASIA） International standards for neurological classification of SCI;（2） patients with SCI who received only stem cell transplantation therapy or stem cell transplantation combined with rehabilitation therapy;（3） one or more of the following outcomes reported： outcomes concerning neurological function including sensory function and locomotor function, activities of daily living, urination functions, and severity of SCI or adverse effects. Studies comprising patients with complications, without full-text, and preclinical animal models were excluded. Quality of the included studies was evaluated using the Cochrane risk of bias assessment tool and Rev Man V5.3 software, provided by the Cochrane Collaboration, was used to perform statistical analysis. OUTCOME MEASURES： ASIA motor score, ASIA light touch score, ASIA pinprick score, ASIA impairment scale grading improvement rate, activities of daily living score, residual urine volume, and adverse events.RESULTS： Ten studies comprising 377 patients were included in the analysis and the overall risk of bias was relatively low level. Four studies did not detail how random sequences were generated, two studies did not clearly state the blinding outcome assessment, two studies lacked blinding outcome assessment, one study lacked follow-up information, and four studies carried out selective reporting. Compared with rehabilitation therapy, stem cell transplantation significantly increased the lower limb light touch score（odds ratio（OR） = 3.43, 95% confidence interval（CI）： 0.01 – 6.86, P = 0.05）, lower limb pinprick score（OR = 3.93, 95%CI： 0.74 – 7.12, P = 0.02）, ASI grading rate（relative risk（RR） = 2.95, 95%CI： 1.64 – 5.29, P = 0.0003）, and notably reduced residual urine volume（OR = –8.10, 95%CI： –15.09 to –1.10, P = 0.02）. However, stem cell transplantation did not significantly improve motor score（OR = 1.89, 95%CI： –0.25 to 4.03, P = 0.08） or activities of daily living score（OR = 1.12, 95%CI： –1.17 to 4.04, P = 0.45）. Furthermore, stem cell transplantation caused a high rate of mild adverse effects（RR = 14.49, 95%CI： 5.34 – 34.08, P 〈 0.00001）; however, these were alleviated in a short time. CONCLUSION： Stem cell transplantation was determined to be an efficient and safe treatment for SCI and simultaneously improved sensory and bladder functions. Although associated minor and temporary adverse effects were observed with transplanted stem cells, spinal cord repair and axon remyelination were apparent. More randomized controlled trials with larger sample sizes and longer follow-up times are needed to further validate the effectiveness of stem cell transplantation in the treatment of SCI.

小剂量骨髓联合外周血造血干细胞移植治疗重型再生障碍性贫血18例临床研究

目的:探讨小剂量骨髓联合外周血造血干细胞(PBSC)移植治疗重型再生障碍性贫血(SAA)的疗效及安全性。方法:纳入以小剂量骨髓(中位体积200 mL)联合PBSC移植治疗的18例SAA患者的临床资料,回顾分析其造血重建情况、移植物抗宿主病(GVHD)发生率、感染发生率及生存率等指标。结果:18例患者的中位年龄27(13~52)岁,男11例,女7例;SAA-Ⅰ型15例,SAA-Ⅱ型3例;单倍体相合供者15例,同胞全相合供者3例;预处理:氟达拉滨+环磷酰胺+抗人胸腺球蛋白方案2例,氟达拉滨+环磷酰胺+移植后环磷酰胺方案8例,氟达拉滨+环磷酰胺+抗人胸腺球蛋白+移植后环磷酰胺方案8例;采用环孢素或他克莫司+短疗程甲氨蝶呤联合吗替麦考酚酯预防GVHD。所有患者均获得造血重建,仅1例患者出现继发性移植物功能不良;10例(55.6%)出现总计19例次移植后感染,其中10例次为巨细胞病毒(CMV)或EB病毒(EBV)血症,6例次细菌感染;急性GVHD发生率为16.7%,其中Ⅰ度1例,Ⅱ度2例;慢性GVHD发生率为16.7%,均为轻度;中位随访26(2~64)个月,移植后2年总生存率为72.2%(95%CI:51.4~93.0)。5例患者死亡,4例死于肺部感染,1例死于颅内感染。结论:采用小剂量骨髓联合PBSC是SAA患者进行造血干细胞移植的有效且可行的移植物选择策略。

Potential advantages of a combination of Chinese Medicine and bone marrow mesenchymal stem cell transplantation for removing blood stasis and stimulating neogenesis during ischemic stroke treatment

Combined treatment of ischemic stroke with Chinese medicine and exogenous bone marrow mesenchymal stem cell(BMSC) transplantation may improve the removal of blood stasis and stimulation of neogenesis.Chinese medicines that remove blood stasis not only promote blood circulation but also calm the endopathic wind,remove heat,resolve phlegm,remove toxic substances and strengthen body resistance.The medicinal targeting effect of Chinese medicine can promote the homing of BMSCs,and the synergistic therapeutic effects of drugs can contribute to BMSC differentiation.As such,exogenous BMSC transplantation has potential advantages for neogenesis.Chinese medicines and exogenous BMSCs provide complementary functions for the removal of blood stasis and stimulation of neogenesis.Therefore,a combination of Chinese medicine and transplantation of exogenous BMSCs may be particularly suited to ischemic stroke treatment.

同胞脐血和同供者骨髓联合移植治疗儿童重型β-地中海贫血

为了研究同胞脐血和骨髓联合移植治疗儿童重型β-地中海贫血的疗效,用HLA全相合同胞脐血+骨髓移植治疗3例重型β-地中海贫血。供给3例受者的有核细胞细胞数分别为19.5×107/kg、20.8×107/kg和23.3×107/kg。移植的预处理方案:采用马利兰+环磷酰胺+抗胸腺细胞球蛋白方案。结果表明:3例患儿均获得长期稳定植入,中性粒细胞0.5×109/L的时间分别为16、18、17天,血小板50×109/L的时间分别为48、50、49天,造血重建速度较单纯脐血移植快。3例患儿现已脱离了地中海贫血状态生活了1.5、2.0、2.1年,血红蛋白一直维持在正常水平。3例患儿均发生I度急性移植物抗宿主病(aGVHD)。结论:同胞脐血和骨髓联合移植可能作为一种安全和有效的移植方式用于治疗儿童地中海贫血。

血液病骨髓移植后卵巢早衰育龄女性激素补充治疗临床疗效

目的:探讨血液病骨髓移植(BMT)后卵巢早衰(POF)患者行激素补充治疗(HRT)的临床疗效。方法:选择2015年4月至2017年3月于苏州大学附属第一医院妇科门诊就诊的血液病BMT后POF行HRT的44例育龄女性的病例资料,比较其HRT前后月经情况、血管舒缩症状、症状自评量表(SCL-90)、卵泡刺激素(FSH)、黄体生成素(LH)、雌二醇(E_2)、抗苗勒管激素(AMH)、子宫大小、窦卵泡数量(AFC)、乳房钼靶或B超检查以及骨密度的变化情况,初步探讨HRT对这类患者的临床疗效。结果:血液病BMT后发生POF的患者行HRT后,月经复潮率95. 5%,治疗前有血管舒缩症状的患者治疗后症状均缓解(100%),治疗前后症状自评量表(SCL-90)总分和各因子分数差异有统计学意义(P<0. 05)。治疗6个月后AMH数值增加、FSH和LH明显降低、子宫体积增大(P<0. 05),但是AFC无明显变化。治疗1年后复查骨密度的9例患者,L1～L4骨密度无明显变化,双股骨骨密度数值增大(P<0. 05);治疗1年以上的患者有11例随访乳房情况未发现明显变化。结论:血液病BMT后POF的育龄女性行HRT可有效缓解其雌激素缺乏相关症状,建议对这类患者行HRT。

非血缘脐血及骨髓移植治疗儿童血液病的meta分析

目的观察非血缘脐血移植(UCBT)和非血缘骨髓移植(UBMT)对儿童血液病的治疗效果。方法计算机检索Cochrane、Medline、CNKI、CBM在1999-2007年期间发表的关于儿童脐血移植和非血缘骨髓移植的研究文献。从干细胞植入、移植并发症、早期死亡、生存率等方面对比分析了UCBT和UBMT的临床疗效。采用Review Manager 4.2软件进行meta分析,发表性偏倚采用倒漏斗图(funnel plot)显示。结果检索出292篇文献,最终纳入6个试验共668例患儿。UCBT与UBMT相比,因植入延迟使植入失败率增高、早期移植相关死亡率增加,但巨细胞病毒(CMV)感染并未明显增加,而慢性移植物抗宿主病(GVHD)减少使两者的长期生存率相似。结论儿童UCBT和UBMT移植后的长期生存率无明显区别,目前文献表明,UCBT也是儿童血液病的有效治疗方法。

自体外周血造血干细胞联合自体骨髓移植治疗难治性淋巴瘤的临床分析

本研究通过回顾性分析自体外周造血干细胞移植、自体骨髓移植及二者联合移植在治疗难治性恶性淋巴瘤的疗效、毒副作用、造血和免疫功能恢复速度等临床方面的差异,总结归纳三种不同移植方式在治疗难治性淋巴瘤方面的优劣。68例难治性恶性淋巴瘤患者接受了大剂量放化疗结合自体造血干细胞移植治疗,其中10例患者为单一自体骨髓移植(autologous bone marrow transplantation,ABMT),46例患者为单一自体外周血造血干细胞移植(autologous peripheral blood hematopoietic stem cell transplantation,APBHSCT),12例患者为自体外周血造血干细胞联合自体骨髓移植(autologous peripheral blood hematopoietic stem cells transplantation combined with autologous bone marrow transplantation,APBHSCT+ABMT)。结果表明:ABMT、APBHSCT、APBHSCT+ABMT的治疗有效率和1、3、5年生存率分别为(90%和75%、57.1%、33.3%);(86.4%和74.4%、54.2%、38.1%);(83.3%和72.7%、55.6%、40%)。白细胞恢复时间分别为13天、11天、8天,血小板恢复时间分别为17天、14天、9天。在移植后3个月、6个月、1年时检测ABMT、APBHSCT、APBHSCT+ABMT患者T细胞亚群正常率分别为(0%、33.3%、60%),(10.8%、32%、73.9%),(27.3%、55.6%、85.7%)。结论:自体外周血造血干细胞联合自体骨髓移植与单一自体外周造血干细胞移植治疗难治性恶性淋巴瘤的临床疗效和毒副作用相当,但联合造血干细胞移植(APBHSCT+ABMT)患者的造血功能恢复略快,有利于拓宽年龄偏大和造血功能受损患者移植方式的选择。

HLA单倍体外周血联合骨髓干细胞移植治疗急性混合细胞白血病的临床观察

目的探索急性混合细胞白血病人类白细胞抗原（HLA）单倍体造血干细胞移植治疗方法及疗效观察。方法对4例急性混合细胞白血病患者进行HLA单倍体外周血造血干细胞联合骨髓移植治疗，观察移植疗效及相关并发症。结果所有患者均成功重建造血。中性粒细胞及血小板恢复中位时间分别为16．5d（14～21d）、16．5d（15～30d）。1例PR患者移植后完全缓解，其余3例持续缓解。2例移植过程中发生急性GVHD，未观察到慢性GVHD的发生。1例患者在移植过程中发生单一的APTT延长。中位随访时间181d（129～337d），1例于移植后190d死于真菌感染，1例CR2和1例PR分别于移植后183d和129d病情复发，另1例无病存活337d。结论HLA单倍体外周血造血干细胞联合骨髓移植治疗急性混合细胞白血病切实可行，但需积累更多的资料以进一步观察疗效。

同种异基因小鼠骨髓腔内脐血移植模型的建立及其对造血干细胞植入的影响

【目的】建立同种异基因小鼠骨髓腔内脐血移植模型，研究该技术对造血干细胞(HSC)归巢、植入率、移植后免疫造血重建、移植物抗宿主病(GVHD)等方面的影响。【方法】用C57BL／6胎鼠及新生鼠外周血(FNPB)作供体，以单侧胫骨骨髓腔内注射(IBMI)和尾静脉注射(IV)两种途径移植经亚致死量^(60)Coγ射线辐照预处理的BALB／c鼠。200只受鼠随机分为4组：骨髓腔内注射组(IBM组)；尾静脉注射组(IV组)；放疗对照组；正常对照组，每组50只。用组织冰冻切片和流式细胞术动态了解CFSE标记FNPB在受体内的分布变化，并观察移植后受鼠存活状况、植入水平、造血与免疫功能恢复及GVHD情况。【结果】①荧光际记FNPB体内动力学显示直至输注后72h，供体FNPB经IBMI后主要积聚于注射侧骨髓腔内，肺部滞留很少。而IV组及IBM组非注射侧骨髓中的FNPB细胞数显著少于IBM组注射侧，IV组非造血组织器官如肺部有明显供体细胞滞留。②同种异基因小鼠CBT模型中IBM组造血、免疫功能的恢复明显快于IV组，无GVHD，移植后90d存活率达到90％，注射侧胫骨植入水平(29.53±6.64)％，较IV组有显著改善。③IBM输注侧骨髓中供体HSCs植入水平及造血重建速度明显优于非注射侧骨髓。【结论】成功建立同种异基因小鼠骨髓腔内脐血移植模型，并证实IBMI途径对促进HSCs植入，造血免疫功能重建，提高UCBT效果方面优于IV途径，多部位IBMI可能更有利于HSC归巢骨髓。

骨髓腔内注射造血干细胞移植的研究和应用进展

骨髓腔内注射造血干细胞移植旨在促进HSC的归巢。近年来已有大量的动物实验肯定了不同来源供体细胞通过骨髓腔内注射能有效地归巢并植入骨髓、迅速重建受体造血和免疫功能、减少GVHD,诱导同种异基因器官移植免疫耐受,提高受体生存率。本文主要对该技术在骨髓移植、脐血移植、研究HSC生物学特性等方面的作用以及临床应用前景进行综述。

造血干细胞捐献登记国际比较研究

造血干细胞捐献登记是为需要骨髓移植病人找到合适HLA配型的有效途径。本文通过网络检索和文献复习的方法获取数据 ,分析了国际造血干细胞捐献者资料库的现状。结果显示 ,捐献者登记人数逐年上升 ,不同地区存在较大差异 ,其中北美和欧洲有着较好的基础。

不同的造血干细胞移植方式对重型再生障碍性贫血治疗效果的影响

目的:比较异基因外周造血干细胞移植(Allo-PBSCT)、异基因骨髓移植(Allo-BMT)及Allo-PBSCT和Allo-BMT混合移植3种不同的移植方式治疗重型再生障碍性贫血(SAA)的临床效果。方法:37例SAA患者接受了同胞人类白细胞抗原(HLA)全相合异基因干细胞移植,其中Allo-PBSCT组11例,Allo-BMT组14例,混合移植组12例。观察所有患者移植近期中性粒细胞(Neu)和血小板的造血时间、短小片段重复序列(STR)植入状况、粒细胞缺乏(粒缺)合并感染的发生率、急慢性移植物抗宿主病(GvHD)发生率,以及远期3年植入失败率、病死率和无病生存率。结果:Allo-PBSCT组、Allo-BMT组、混合移植组的Neu造血时间分别为(13.5±2.3)d、(21.2±3.5)d和(14.7±2.4)d,血小板造血时间分别为(24±4)d、(22±5)d和(23±5)d,Allo-PBSCT组和混合移植组的Neu造血时间均短于Allo-BMT组(P均<0.05),而3组间血小板平均造血时间比较差异无统计学意义。3组所有患者在移植后第28日时检测STR均证实为完全供者嵌合体。Allo-PBSCT组和混合移植组粒缺合并感染发生率分别为9%和17%,均明显低于Allo-BMT组的57%(P均<0.05);Allo-PBSCT组GvHD总发生率(包括急性和慢性)为36%,与均无GvHD发生的Allo-BMT组及混合移植组比较差异具统计学意义(P均<0.05);Allo-PBSCT组3年的植入失败率、病死率和无病生存率分别为36%、9%和64%,混合移植组和Allo-BMT组所有患者3年内均无病生存、STR均表现为稳定植入,Allo-PBSCT组3年植入失败率高于混合移植组和Allo-BMT组(P均<0.05),3年无病生存率低于混合移植组和Allo-BMT组(P均<0.05)。结论:在上述3种不同的移植方式中,混合移植同时具有Neu重建快、粒缺合并感染发生率低、GvHD发生率和植入失败发生率低、无病生存率高等优点,临床上可以优先考虑采用此方式进行治疗。

活血生肌汤联合自体骨髓血干细胞移植对糖尿病足创面的修复作用研究

目的:研究活血生肌汤联合自体骨髓血干细胞移植对糖尿病足创面的修复作用。方法:选取74例糖尿病足患者,均行常规内科治疗,分为对照组(采取自体骨髓血干细胞移植)和研究组(采取活血生肌汤联合自体骨髓血干细胞移植治疗),两组各37例。比较两组患者治疗前后血糖水平、患足溃疡面积、下肢神经传导速度和治疗后间歇性跛行、足冷感觉、静息疼及愈合情况等差异。结果:研究组治疗后血糖水平较对照组明显降低(P<0.05),治疗后间歇性跛行、足冷感觉、静息疼较对照组均明显改善(P<0.05)。研究组治疗后患足溃疡面积较对照组明显减少,愈合率较对照组明显升高(P<0.05)。研究组治疗后下肢正中神经传导速度和腓神经传导速度较对照组均明显加快(P<0.05)。结论:采取活血生肌汤联合自体骨髓血干细胞移植可有效改善糖尿病足患者治疗效果,促进创面愈合,加快血管新生,有助于尽快建立侧支循环,取得良好的临床疗效。

骨髓腔内途径脐血与间质干细胞共移植对造血重建的实验研究

目的:探讨骨髓腔内输注(IBM)脐血与间质干细胞(MSCs)对大鼠造血重建、骨髓MSCs恢复的影响,并研究供体MSCs植入状态以探讨MSCs的作用机制。方法:BrdU标记F344大鼠骨髓MSCs通过双侧胫骨IBM或尾静脉注射(IV)与胎鼠及新生大鼠外周血(FNPB)共移植Wistar雌鼠。监测受鼠存活状况、造血免疫重建、HSCs植入水平及骨髓MSCs恢复情况,并以免疫荧光法检测受鼠骨髓MSCs的来源。结果:(1)2个共移植组60d存活率均为100%,单纯FNPB移植组仅为66.7%。(2)共移植组的外周血象、骨髓造血干祖细胞集落产率明显高于单纯FNPB移植组,尤以骨髓腔共移植组最佳。(3)2个共移植组的HSCs植入水平无统计学差异,而骨髓腔共移植组明显高于单纯FNPB移植组(P<0.05)。(4)30d时各移植组MSCs的增殖能力未达正常水平,但仍以骨髓腔共移植组的恢复情况最佳(P<0.05)。(5)仅少部分受体可发现供、受体源性MSCs嵌合。结论:脐血与MSCs共移植可促进受体骨髓MSCs恢复和造血重建,提高HSCs植入率;IBM途径应用安全,促进造血恢复的作用优于IV途径。